Mirum Pharmaceuticals, Inc. has entered into a subscription agreement with entities associated with TCGX for a private placement of 1,000,000 shares of its common stock at $68.48 per share for approximately $68.5 million in gross proceeds.
The proceeds from this private placement, combined with a previous $200 million private placement, are intended to fund clinical development and commercial activities post the proposed acquisition of Bluejay Therapeutics, a biotechnology company focused on viral and liver diseases.
Both private placements are expected to close concurrently with the proposed acquisition of Bluejay in the first quarter of 2026.
Private Placement Details
1,000,000 shares of common stock priced at $68.48 per share for $68.5 million in gross proceeds.
Funding Purpose
Proceeds to fund clinical development and commercial activities post the Bluejay Therapeutics acquisition.
Closing Timeline
Private placements expected to close concurrently with the proposed Bluejay acquisition in Q1 2026.
- The private placement financing with TCGx provides Mirum Pharmaceuticals with additional capital to support its strategic growth and development plans.
- This financing reinforces Mirum's commitment to advancing breakthrough medicines for rare diseases and expanding its global presence in the pharmaceutical industry.
The successful private placement financing and strategic agreements mark a significant step for Mirum Pharmaceuticals in securing the necessary funds for its future endeavors and expansion.